FIELD: biotechnology.
SUBSTANCE: what is presented is using a pharmaceutical composition for treating a disease associated with IL-6, where the pharmaceutical composition contains an IL-6 receptor antibody as an active ingredient. Pharmaceutical composition is administered in a standard dose of 120 mg for administration of an antibody with four-week intervals after a short dose period, when dose similar to standard dose is introduced repeatedly with two-week intervals.
EFFECT: invention provides reduced immunogenicity and side effects, namely suppressing the formation of anti-antibodies by administering the pharmaceutical composition in said dose and according to said method of administration.
6 cl, 4 tbl, 3 ex, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED ANTIBODY AGAINST IGF-1 RECEPTOR | 2019 |
|
RU2784079C1 |
| METHODS AND COMPOSITIONS FOR REDUCING IMMUNOGENICITY USING NON-DEPLETION B-CELL INHIBITORS | 2020 |
|
RU2821892C2 |
| HUMAN NOTCH4 ANTIBODY | 2016 |
|
RU2720280C2 |
| COMBINATION OF CELL THERAPY AND IMMUNOMODULATOR COMPOUND | 2018 |
|
RU2777911C2 |
| ANTIGEN-BINDING MOLECULE CAPABLE OF MULTIPLE BINDING OF TWO OR MORE ANTIGEN MOLECULES | 2014 |
|
RU2756029C2 |
| METHODS OF TREATMENT OR PREVENTION OF ASTHMA THROUGH ADMINISTRATION OF IL-4R ANTAGONIST | 2013 |
|
RU2801531C2 |
| AGENT FOR INHIBITING IRON ABSORPTION BY CELLS | 2019 |
|
RU2817146C2 |
| COMBINATION | 2015 |
|
RU2744841C2 |
| PREDICTION OF RISK OF DEVELOPMENT OF UNDESIRED REACTION RELATED TO ADMINISTRATION OF ANTIBODY TO ALK2 AND CAPABILITY OF RESPONDING TO TREATMENT WITH ANTIBODY TO ALK2 | 2019 |
|
RU2783762C2 |
| DOSING REGIMEN OF A WNT INHIBITOR AND AN ANTI-PD-1 ANTIBODY MOLECULE IN A COMBINATION | 2018 |
|
RU2767533C2 |
